Author + information
- Received October 17, 2016
- Revision received November 20, 2016
- Accepted November 28, 2016
- Published online December 9, 2016.
- S0735109716371753-f753599ee4e46b384dd8cd3cf4d9cf98Frederick L. Grover, MD1,∗ (, )
- S0735109716371753-71fd778c38b85376dabd940d99b151adSreekanth Vemulapalli, MD2,
- S0735109716371753-6dc79eaefb1a78b9a6c156f0246dd16aJohn D. Carroll, MD3,
- S0735109716371753-e2c295c0eb409a87a525cb1f55400366Fred H. Edwards, MD4,
- S0735109716371753-4cd2819a3bc4f9102b717d14b10b3718Michael J. Mack, MD5,
- S0735109716371753-8c010107180cf1e6c3bfc69551cf9415Vinod H. Thourani, MD6,
- S0735109716371753-61e1784f7b6e8aea089ff50ba8085b5eRalph G. Brindis, MD, MPH7,
- S0735109716371753-999fe8d1a0aced3d0252fa0b5ccca07eDavid M. Shahian, MD8,
- S0735109716371753-0d75506b037e0dd696d97720fc6ca6acCarlos E. Ruiz, MD9,
- S0735109716371753-aec6e82003a8ac443cbcc4619b8ffa45Jeffrey P. Jacobs, MD10,
- S0735109716371753-8c53db11db20d1cb835a40158b56a411George Hanzel, MD11,
- S0735109716371753-95d0e6d95fe552f2d1ce4047ff03cba0Joseph E. Bavaria, MD12,
- S0735109716371753-d8ff24d78729a4c58fb4425c4d48952aE. Murat Tuzcu, MD13,
- S0735109716371753-787e8559bdeba835815f96bb33498ec2Eric D. Peterson, MD, MPH2,
- S0735109716371753-63f3ac3d015c77bd270781c7fe748ea5Susan Fitzgerald, RN, MS14,
- S0735109716371753-1f08763bc34a167fb67e68828f9c05ddMatina Kourtis, MS15,
- S0735109716371753-b87b59c0acc6418744ddd08a17b814a9Joan Michaels, RN, MSN14,
- S0735109716371753-2b84898c256b75207332faa31fb5a660Barbara Christensen, MSHA, RN14,
- S0735109716371753-61e733d35b081612e0f1bcd903202920William F. Seward, MA15,
- S0735109716371753-a63e9a9880ea49972dd5422fb0e7b136Kathleen Hewitt, MSN, RN14,
- S0735109716371753-22d5ed43f8c30d5e09a8d65ddce803c1David R. Holmes Jr., MD16,
- STS/ACC TVT Registry
- 1University of Colorado, Anschutz Medical Campus, School of Medicine, Dept. of Surgery, Denver Department of Veterans Affairs Medical Center, Aurora, Colorado, Denver, CO
- 2Duke University Medical Center, Durham, North Carolina
- 3University of Colorado, Anschutz Medical Campus, School of Medicine, Aurora, CO
- 4University of Florida, Jacksonville, Florida
- 5Baylor Scott and White Health, Plano, Texas
- 6Emory University, Atlanta, Georgia
- 7University of California, San Francisco, California
- 8Massachusetts General Hospital, Boston, Massachusetts
- 9Director, Structural and Congenital Heart Center, Hackensack University Medical Center and, The Joseph M. Sanzari Children’s Hospital, Professor of Cardiology in Pediatrics and Medicine, Seton Hall Hackensack University – School of Medicine, Hackensack, New Jersey
- 10Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, and Division of Cardiovascular Surgery, Department of Surgery, Johns Hopkins All Children’s Heart Institute, All Children’s Hospital and Florida Hospital for Children, Baltimore, MD, St. Petersburg, Tampa and Orlando, Florida
- 11Beaumont Hospital, Royal Oak, Michigan
- 12Division of Cardiovascular Surgery, University Of Pennsylvania, Philadelphia, Pennsylvania
- 13Cleveland Clinic, Abu Dhabi
- 14American College of Cardiology, Washington, DC
- 15The Society of Thoracic Surgeons, Chicago, Illinois
- 16Mayo Clinic, Rochester, Minnesota
- ↵∗Corresponding Author: Frederick L. Grover, MD University of Colorado School of Medicine Anschutz Medical Campus, Dept. of Surgery Academic Office 1, Room 6613 12631 E. 17th Ave.,MSC310 Aurora, Colorado 80045.
Background The STS/ACC Transcatheter Valve Therapy (TVT) Registry captures all procedures with Food and Drug Administration (FDA) approved transcatheter valve devices performed in the United States and is mandated as a condition of reimbursement by a Centers for Medicaid and Medicare Services (CMS)
Objectives This annual report focuses on patient characteristics, trends, and outcomes of transcatheter aortic and mitral valve catheter-based valve procedures in the United States.
Methods Data for all patients receiving commercially approved devices from 2012 through December 31, 2015 are entered in the TVT Registry.
Results The 54,782 TAVR patients demonstrated decreases in expected risk of 30-day operative mortality (STS PROM) 7% to 6% and TAVR PROM (TVT PROM) 4% to 3% (both p<.0001) from 2012 to 2015. Observed in-hospital mortality decreased from 5.7% to 2.9% and one-year mortality decreased from 25.8% to 21.6. However, 30-day post procedure pacemaker insertion increased from 8.8% in 2013 to 12.0% in 2015. The 2,556 patients who underwent TMC in 2015 were similar to 2013-14 patients with hospital mortality of 2% with mitral regurgitation reduced to gradient ≤ 2 in 87% of patients (p<.0001). The 349 patients who underwent MViV and MViR procedures were high risk with, an STS PROM for MVR of 11%. The observed hospital mortality was 7.2% and 30-day post procedure was 8.5%.
Summary The TVT Registry is an innovative registry that that monitors quality, patient safety and trends for these rapidly evolving new technologies.
Condensed Abstract The STS/ACC TVT Registry captures all Food and Drug Administration (FDA) approved transcatheter valve devices preformed in the United States and is mandated as a condition for reimbursement by the Centers for Medicare Services. TAVR patients’ expected risks of mortality and actual in-hospital mortality decreased. Transcatheter mitral clip procedures had a low mortality with reduced in mitral regurgitation to grade ≤ 2 in 87%. Mitral valve in valve or valve in ring patients were high risk for mortality, but actual hospital mortality was lower. The TVT Registry is an innovative registry that monitors quality, safety and trends of these evolving technologies
- Transcatheter Valves
- Transcatheter Mitral Clip
- Valve in Valve
- Procedural Risk
- Procedural Outcomes
- Received October 17, 2016.
- Revision received November 20, 2016.
- Accepted November 28, 2016.